Alberto de Leiva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alberto de Leiva has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Antonio Pérez
From the Department of Endocrinology and Nutrition, Universitat Autònoma de Barcelona, Spain
1 shared publicationAscension Lupianez
1 shared publicationCarmen Martinez
1 shared publicationCintia Gonzalez
1 shared publication- Didac Mauricio
CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Barcelona, Spain
1 shared publication Eulàlia Brugués
1 shared publication
Latest Publications
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Intensified telematic treatment for obesity using the web platform PREDIRCAM2, descriptive basal characteristics and preliminary results
Background: PREDIRCAM2 is a web platform for obesity treatment and follow-up. It contains modules for: dietary prescription and registry with nutritional analysis based on individualized and mediterranean dietary goals, physical activity prescription and tracking with individualized targets, and anthropometric tracking. An ongoing multicenter randomized clinical trial evaluates the intervention’s effectiveness in obesity treatment and cardio-metabolic-risk prevention. Methods: Inclusion criteria: 18–65 years-old, BMI 30–39.9 kg/m2, no medication for type-2 Diabetes Mellitus (DM), dyslipidemia (DLP) or hypertension (HT). Randomization to intensified technological intervention (TI) supported by PREDIRCAM2 platform, or traditional non-technological face-to-face intensified treatment intervention (NTI). Both groups receive one year follow-up through 12 appointments with health-care professionals, 4 of which are exclusively telematic in the TI group. Basal characteristics: 183 participants have been included, BMI 34.74±2.74, age 44.27±10.62, 84% female (31% postmenopausal, 6.5% history of gestational DM), 54% high education level, 54% married. Comorbidities: 2.2% type-2 DM, 5.5% HT, 11.5% DLP, 6.5% Depression, 2.7% diagnosed eating disorders. 56% received medication, most frequently antidepressants (24.5%) followed by vitamin D supplements (11.8%). 68% reported anxiety towards food, overeating in the form of: pecking 84.7%, binge-eating 35.5%, binge-and-vomiting 3.2%. Preliminary results: 119 participants have completed 3-month follow-up: 60 TI, 59 NTI. Both groups have lost weight significantly (PP=0.88). 81 participants have completed 6-month follow-up: 41 TI, 40 NTI. Both groups have lost weight significantly (P< 0.0001). 46.3% TI, and 32.5% NTI have achieved at least a 5% weight-loss (P=0.20). Both groups have achieved a reduction in HbA1c levels (PP=0.24). Conclusion: Our study population is mostly composed of highly educated females who report a high frequency of anxiety towards food and eating. PREDIRCAM2 shows to be a promising tool for obesity treatment and cardio-metabolic-risk prevention.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Intensified telematic treatment for obesity using the web platform PREDIRCAM2, descriptive basal characteristics and preliminary results
Background: PREDIRCAM2 is a web platform for obesity treatment and follow-up. It contains modules for: dietary prescription and registry with nutritional analysis based on individualized and mediterranean dietary goals, physical activity prescription and tracking with individualized targets, and anthropometric tracking. An ongoing multicenter randomized clinical trial evaluates the intervention’s effectiveness in obesity treatment and cardio-metabolic-risk prevention. Methods: Inclusion criteria: 18–65 years-old, BMI 30–39.9 kg/m2, no medication for type-2 Diabetes Mellitus (DM), dyslipidemia (DLP) or hypertension (HT). Randomization to intensified technological intervention (TI) supported by PREDIRCAM2 platform, or traditional non-technological face-to-face intensified treatment intervention (NTI). Both groups receive one year follow-up through 12 appointments with health-care professionals, 4 of which are exclusively telematic in the TI group. Basal characteristics: 183 participants have been included, BMI 34.74±2.74, age 44.27±10.62, 84% female (31% postmenopausal, 6.5% history of gestational DM), 54% high education level, 54% married. Comorbidities: 2.2% type-2 DM, 5.5% HT, 11.5% DLP, 6.5% Depression, 2.7% diagnosed eating disorders. 56% received medication, most frequently antidepressants (24.5%) followed by vitamin D supplements (11.8%). 68% reported anxiety towards food, overeating in the form of: pecking 84.7%, binge-eating 35.5%, binge-and-vomiting 3.2%. Preliminary results: 119 participants have completed 3-month follow-up: 60 TI, 59 NTI. Both groups have lost weight significantly (PP=0.88). 81 participants have completed 6-month follow-up: 41 TI, 40 NTI. Both groups have lost weight significantly (P< 0.0001). 46.3% TI, and 32.5% NTI have achieved at least a 5% weight-loss (P=0.20). Both groups have achieved a reduction in HbA1c levels (PP=0.24). Conclusion: Our study population is mostly composed of highly educated females who report a high frequency of anxiety towards food and eating. PREDIRCAM2 shows to be a promising tool for obesity treatment and cardio-metabolic-risk prevention.
- 1 March 2008
- Published by Taylor & Francis
- p. 399-408
Quality of care for the woman with diabetes in pregnancy
- 1 March 2008
- Published by Taylor & Francis
- p. 399-408
Quality of care for the woman with diabetes in pregnancy
- Open Access
- 1 July 2007
- Published by American Diabetes Association in Diabetes Care
- Vol. 30 (Supplement) , S127-S133
Diabetes-Related Autoantibodies and Gestational Diabetes
- 1 July 2007
- Published by American Diabetes Association in Diabetes Care
- Vol. 30 (Supplement) , S127-S133
Open AccessDiabetes-Related Autoantibodies and Gestational Diabetes
- 1 January 2000
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 84 (08) , 223-227
Normalisation of Tissue Factor Pathway Inhibitor Activity after Glycaemic Control Optimisation in Type 1 Diabetic Patients
Increased plasma concentrations of various markers of endothelial damage have been observed in type 1 diabetic patients, particularly in those with microangiopathy. Objective. To evaluate the effect of nearnormalisation of glycaemic control on different markers of endothelial injury involved in haemostasis in poorly-controlled type 1 diabetic patients. Material and Methods. TFPI, thrombomodulin (TM), plasminogen activator inhibitor, tissue-type plasminogen activator and von Willebrand factor were measured in 14 poorly-controlled type 1 diabetic patients free of diabetes-related complications (8 men, 6 women; mean age 29.8 ± 9.9 years) before (baseline) and after 3 months of intensive therapy and in 14 sex-, age-and BMI-matched control subjects. Results. After a mean follow-up of 107 ± 49 days (56-210), Hb A1c decreased from 11.2 ± 2.3 to 6.7 ± 0.7% (p 1c (p <0.05; r = 0.54). TM levels at baseline were significantly higher than in the control group (42.3 ± 9.1 vs 29.00 ± 10.9; p <0.005) and did not change. The remaining parameters studied were similar between patients and controls and did not change after glycaemic optimisation. Conclusions. Optimisation of glycaemic control normalises the increased activity of TFPI but not the higher TM levels observed in poorly-controlled type 1 diabetic patients without chronic complications.
- 1 January 2000
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 84 (08) , 223-227
Normalisation of Tissue Factor Pathway Inhibitor Activity after Glycaemic Control Optimisation in Type 1 Diabetic Patients
Increased plasma concentrations of various markers of endothelial damage have been observed in type 1 diabetic patients, particularly in those with microangiopathy. Objective. To evaluate the effect of nearnormalisation of glycaemic control on different markers of endothelial injury involved in haemostasis in poorly-controlled type 1 diabetic patients. Material and Methods. TFPI, thrombomodulin (TM), plasminogen activator inhibitor, tissue-type plasminogen activator and von Willebrand factor were measured in 14 poorly-controlled type 1 diabetic patients free of diabetes-related complications (8 men, 6 women; mean age 29.8 ± 9.9 years) before (baseline) and after 3 months of intensive therapy and in 14 sex-, age-and BMI-matched control subjects. Results. After a mean follow-up of 107 ± 49 days (56-210), Hb A1c decreased from 11.2 ± 2.3 to 6.7 ± 0.7% (p 1c (p <0.05; r = 0.54). TM levels at baseline were significantly higher than in the control group (42.3 ± 9.1 vs 29.00 ± 10.9; p <0.005) and did not change. The remaining parameters studied were similar between patients and controls and did not change after glycaemic optimisation. Conclusions. Optimisation of glycaemic control normalises the increased activity of TFPI but not the higher TM levels observed in poorly-controlled type 1 diabetic patients without chronic complications.